On September 18, 2025, McKesson Corp announced changes to its financial reporting structure, introducing four reportable segments to better allocate resources and assess performance from the second quarter of fiscal 2026. This restructuring includes segments for North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, but does not affect previously issued financial statements.